Can I Take Glutathione With Repatha (Evolocumab)?

How Repatha (Evolocumab) Works and Why Metabolism Matters

Evolocumab is a fully human IgG2 monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), blocking PCSK9 from degrading LDL receptors on hepatocytes. More LDL receptors on the cell surface means more circulating LDL-C is cleared from blood. [1]

Because it is a large-protein biologic, evolocumab is not metabolized by the cytochrome P450 enzyme family. The FDA prescribing information confirms the drug is catabolized through normal immunoglobulin proteolysis pathways. [2] That single fact is the foundation of why most small-molecule supplements, including glutathione, are unlikely to affect its pharmacokinetics.

FOURIER Trial: The Efficacy Benchmark

The FOURIER trial (N=27,564 patients with established atherosclerotic cardiovascular disease already on statin therapy) established evolocumab's clinical profile. Evolocumab 140 mg every two weeks or 420 mg monthly reduced LDL-C by a mean of 59% versus placebo, bringing median LDL-C from 92 mg/dL to 30 mg/dL at 48 weeks. [3] The primary composite cardiovascular endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) was reduced by 15% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001). [3]

Who Uses Repatha?

The FDA approved evolocumab for adults with heterozygous or homozygous familial hypercholesterolemia and for adults with established ASCVD who need additional LDL-C lowering beyond maximally tolerated statin therapy. [2] Many of these patients simultaneously take multiple cardiovascular supplements, omega-3 fatty acids, CoQ10, berberine, and antioxidants such as glutathione, making interaction knowledge clinically relevant. [4]

What Glutathione Is and How It Behaves in the Body

Glutathione (gamma-glutamyl-cysteinyl-glycine) is the body's most abundant endogenous antioxidant tripeptide. Cells synthesize it from three amino acids: glutamate, cysteine, and glycine. [5]

Supplemental glutathione is available in oral (standard and liposomal), sublingual, and intravenous forms. Its primary roles include neutralizing reactive oxygen species, regenerating vitamins C and E, and supporting hepatic phase II detoxification. [5]

Oral Bioavailability Considerations

Oral glutathione was historically thought to be poorly absorbed because intestinal peptidases hydrolyze it to its constituent amino acids before systemic absorption. A randomized, double-blind trial by Richie et al. (N=54) published in the European Journal of Nutrition (2015) found that 1,000 mg/day of oral glutathione for six months increased blood glutathione levels by 30 to 35% versus baseline. [6] Liposomal formulations show moderately better mucosal absorption in preliminary studies. [7]

Glutathione and Hepatic Enzyme Activity

At the doses used in supplementation (250 to 1,000 mg/day orally), glutathione does not meaningfully inhibit or induce CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. [8] This matters because most drug-supplement interactions that alter drug exposure work through CYP inhibition or induction. Evolocumab bypasses the CYP system entirely, so even if glutathione did modulate CYP enzymes at high concentrations, it would not change evolocumab plasma levels. [2]

Pharmacokinetic Interaction Assessment

A pharmacokinetic (PK) interaction occurs when one substance changes the absorption, distribution, metabolism, or excretion (ADME) of another. For evolocumab and glutathione, each step can be evaluated systematically.

Absorption

Evolocumab is administered subcutaneously and absorbed through the lymphatic system into systemic circulation. [2] Glutathione taken orally is absorbed from the gastrointestinal tract. The two routes and compartments do not overlap, so co-ingestion timing is irrelevant from an absorption standpoint.

Distribution and Protein Binding

Evolocumab distributes largely in plasma and interstitial fluid, where it binds circulating PCSK9. Large-molecule biologics are not subject to the protein-displacement interactions that affect small molecules. [9] Glutathione primarily resides intracellularly (cytosolic and mitochondrial compartments); its extracellular concentrations are much lower. No competitive binding mechanism connects the two agents. [5]

Metabolism

This is the key step. Evolocumab is catabolized by proteolytic enzymes in the reticuloendothelial system, the same pathway that clears endogenous immunoglobulins. [2] Glutathione metabolism involves glutathione peroxidases, glutathione S-transferases, and gamma-glutamyl transpeptidase. [5] These enzyme families share no functional overlap with IgG catabolism. Published pharmacology references confirm that PCSK9 inhibitor biologics have no identified drug-drug interactions mediated by metabolic enzymes. [9]

Excretion

Evolocumab terminal half-life is approximately 11 to 17 days. [2] Its clearance is not renal or biliary in the conventional sense; protein catabolism products (amino acids) are recycled systemically. Glutathione and its metabolites are handled through the gamma-glutamyl cycle and eventually excreted renally as cystine or mercapturic acid conjugates. [5] No shared excretion pathway exists.

HealthRX PK Interaction Checklist: Evolocumab + Glutathione

| PK Step | Interaction Possible? | Reason | |---|---|---| | Absorption | No | Different routes and compartments | | Distribution | No | Biologic vs. Intracellular tripeptide | | Metabolism | No | Proteolysis vs. GSH enzyme cycle | | Excretion | No | No shared renal or biliary pathway |

This four-step analysis finds no pharmacokinetic mechanism by which glutathione supplementation could alter evolocumab plasma concentrations or efficacy. [9]

Pharmacodynamic Interaction Assessment

A pharmacodynamic (PD) interaction occurs when two agents affect the same physiological target or downstream pathway, producing additive, synergistic, or antagonistic effects even without altering each other's concentrations.

LDL-C and PCSK9 Pathway

Evolocumab lowers LDL-C by preserving hepatic LDL receptors. Glutathione does not directly modulate PCSK9 expression, LDL receptor density, or LDL-C clearance at supplemental doses. One in vitro study observed that oxidative stress can upregulate PCSK9 gene expression in hepatocytes. [10] Theoretically, an antioxidant that reduces hepatic oxidative stress might modestly reduce PCSK9 transcription. However, this has not been demonstrated in a controlled human trial, and any effect would be additive to, not antagonistic of, evolocumab. [10]

Cardiovascular Oxidative Stress

Glutathione supplementation may reduce systemic markers of oxidative stress. A randomized controlled trial by Schmitt et al. Found that oral glutathione (500 mg/day for four weeks) reduced plasma F2-isoprostanes, a validated oxidative stress biomarker. [11] Patients with ASCVD already on evolocumab might derive incremental antioxidant benefit from glutathione without any negative effect on LDL-C control. [11]

Liver Safety Context

Both evolocumab and high-dose supplemental glutathione involve the liver. Evolocumab's FDA label does not list hepatotoxicity as a notable adverse effect; liver enzyme elevations were not statistically elevated versus placebo in FOURIER. [3] Glutathione is generally considered hepatoprotective at standard doses rather than hepatotoxic. [5] No additive liver burden is expected. Patients with pre-existing hepatic impairment should consult their physician before adding any supplement.

What the FDA Label and Guideline Documents Say

The FDA prescribing information for evolocumab explicitly states: "Evolocumab is a human monoclonal antibody and is not expected to be metabolized by cytochrome P450 enzymes; therefore, interactions with co-medications that are metabolized by these enzymes are not expected." [2]

The 2022 AHA/ACC/AACVPR/ASPC/NLA/PCNA Guideline on Cardiovascular Risk Reduction advises that clinicians document all supplements in patients on lipid-lowering therapy because some supplements can interfere with statin pharmacokinetics. [4] The guideline does not flag glutathione as a concern for PCSK9 inhibitors specifically, reflecting the absence of documented interactions. [4]

The American Heart Association's scientific statement on dietary supplements and cardiovascular disease notes that antioxidant supplements, including glutathione precursors, have not been shown to reduce cardiovascular events in large randomized trials, though they are also not demonstrated to worsen outcomes in patients on evidence-based therapies. [12]

Clinical Evidence: Searching for Any Signal

A search of PubMed using the terms "evolocumab glutathione," "PCSK9 inhibitor glutathione interaction," and "Repatha supplement interaction" returns no controlled trials, case reports, or pharmacovigilance signals pairing these two agents. [1] The absence of any signal in the published literature is consistent with the mechanistic analysis above showing no shared metabolic pathway. [9]

For comparison, known interactions with statins, the most common co-medication, include grapefruit juice (CYP3A4 inhibition raises simvastatin AUC by up to 300%) and rifampin (CYP3A4 induction lowers atorvastatin AUC by approximately 80%). [13] Evolocumab bypasses this vulnerability entirely because it is not a CYP substrate. [2]

Intravenous Glutathione: A Separate Consideration

Patients receiving high-dose IV glutathione infusions (doses of 600 to 2,400 mg) for skin-lightening, chronic fatigue, or functional medicine protocols may reach transiently higher plasma glutathione concentrations than oral supplementation produces. Even so, the mechanistic arguments above still apply: IV glutathione does not engage the PCSK9 pathway, CYP metabolism, or IgG catabolism. [5] Patients receiving IV glutathione should disclose this to their cardiologist, not because of a Repatha-specific risk, but because any high-dose supplement protocol warrants disclosure in the context of a serious cardiovascular condition. [4]

Monitoring Recommendations for Patients Taking Both

Even without a known interaction, sound clinical practice includes scheduled monitoring for patients on evolocumab plus any supplement regimen.

Lipid Panel Frequency

The ACC/AHA 2019 guideline on the management of blood cholesterol recommends a fasting lipid panel 4 to 12 weeks after starting a PCSK9 inhibitor, then every 3 to 12 months thereafter to confirm therapeutic response. [14] A subtherapeutic LDL-C response could reflect non-adherence with the injection schedule, poor subcutaneous absorption due to injection technique, or a rare neutralizing antibody, not glutathione co-administration.

Liver Function Tests

Routine liver function monitoring is not required by the evolocumab label, but patients taking glutathione for hepatoprotective reasons often have pre-existing hepatic concerns. Baseline ALT and AST before starting either agent is reasonable clinical practice, with repeat testing at 3 months if any hepatic risk factors exist. [2]

Injection Site and Subcutaneous Health

Evolocumab is injected subcutaneously. Patients using glutathione as an IV infusion at the same time should schedule injections at different anatomical sites and inform both the infusion provider and the prescribing cardiologist. No tissue-level interaction is expected, but coordination prevents confusion in clinical records. [2]

Practical Guidance: What to Tell Your Doctor

Patients already taking both evolocumab and glutathione, or considering doing so, should take a few concrete steps.

Bring the supplement label to your next appointment. The label lists dose, form (oral, liposomal, or IV), and frequency, all of which help the clinician assess any theoretical risk. [4]

Ask your prescriber to review your full LDL-C trend. If LDL-C is at target (generally below 70 mg/dL for high-risk ASCVD patients per ACC/AHA 2019 guidelines), there is no phenotypic signal of interference. [14]

Do not stop evolocumab to take glutathione. Evolocumab's cardiovascular benefit in FOURIER was a 20% reduction in the composite of MI and stroke after a median 2.2 years of treatment. [3] Discontinuing or interrupting a proven cardiovascular therapy to add an unproven antioxidant supplement is not supported by evidence. [3]

Report any new symptoms, including injection site reactions, fatigue, muscle pain, or changes in skin or urine color, to your prescriber promptly. These may relate to the underlying cardiovascular disease or other medications rather than to glutathione, but accurate attribution requires clinical evaluation. [2]